LA JOLLA, CA, April 30, 2024 – Enlaza Therapeutics, the first covalent biologic platform company, today announced a $100 million Series A financing. The financing will be used to further...
The company pursued development of a reversible inhibitor of monoamine oxidase (MAOI) for treatment resistant depression. In addition, the company assembled a pipeline of selective cannabinoid compounds for the treatment of pain, glaucoma, and obesity.
CeNeRx BioPharma
Cary, NC
© 2024 Pappas Capital, LLC. ALL RIGHTS RESERVED.